Acute and subacute oral toxicity of artemisinin-hydroxychloroquine sulfate tablets in beagle dogs

References

• Al-Bari, M.A., 2015. Chloroquine analogues in drug discovery: new directions of uses, mechanisms of actions and toxic manifestations from malaria to multifarious diseases. The Journal of Antimicrobial Chemotherapy, 70 (6), 1608–1621.
   PubMed Web of Science ®Google Scholar
• Andreani, J., et al., 2020. In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect. Microbial Pathogenesis, 145, 104228.
   PubMed Web of Science ®Google Scholar
• Ben-Zvi, I., et al., 2012. Hydroxychloroquine: from malaria to autoimmunity. Clinical Reviews in Allergy & Immunology, 42 (2), 145–153.
   PubMed Web of Science ®Google Scholar
• Bonow, R.O., Hernandez, A.F., and Turakhia, M., 2020. Hydroxychloroquine, Coronavirus Disease 2019, and QT Prolongation. JAMA Cardiology, 5 (9), 986–987.
   PubMed Web of Science ®Google Scholar
• Boulware, D.R., et al., 2020. A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19. The New England Journal of Medicine, 383 (6), 517–525.
   PubMed Web of Science ®Google Scholar
• Breiden, B., and Sandhoff, K., 2019. Emerging mechanisms of drug-induced phospholipidosis. Biological Chemistry, 401 (1), 31–46.
   PubMed Web of Science ®Google Scholar
• Cao, R., et al., 2020. Anti-SARS-CoV-2 potential of artemisinins in vitro. ACS Infectious Diseases, 6 (9), 2524–2531.
   PubMed Web of Science ®Google Scholar
• Chorin, E., et al., 2020. The QT interval in patients with COVID-19 treated with hydroxychloroquine and azithromycin. Nature Medicine, 26 (6), 808–809.
   PubMed Web of Science ®Google Scholar
• Della Porta, A., et al., 2020. Acute chloroquine and hydroxychloroquine toxicity: a review for emergency clinicians. The American Journal of Emergency Medicine, 38 (10), 2209–2217.
   PubMed Web of Science ®Google Scholar
• Doyno, C., Sobieraj, D.M., and Baker, W.L., 2021. Toxicity of chloroquine and hydroxychloroquine following therapeutic use or overdose. Clinical Toxicology, 59 (1), 12–23.
   PubMed Web of Science ®Google Scholar
• Edwards, M.H., et al., 1997. Hydroxychloroquine reverses thrombogenic properties of antiphospholipid antibodies in mice. Circulation, 96 (12), 4380–4384.
   PubMed Web of Science ®Google Scholar
• Efferth, T., and Kaina, B., 2010. Toxicity of the antimalarial artemisinin and its dervatives. Critical Reviews in Toxicology, 40 (5), 405–421.
   PubMed Web of Science ®Google Scholar
• Espinola, R., et al., 2002. Hydroxychloroquine reverses platelet activation induced by human IgG antiphospholipid antibodies. Thrombosis and Haemostasis, 87 (03), 518–522.
   PubMedGoogle Scholar
• European Medicines Agency (EMA). 2010. Guideline on repeated dose toxicity.
   Google Scholar
• Gasperetti, A., et al., 2020. Arrhythmic safety of hydroxychloroquine in COVID-19 patients from different clinical settings. EP Europace, 22 (12), 1855–1863.
   PubMed Web of Science ®Google Scholar
• Hu, C., et al., 2017. The pharmacological mechanisms and therapeutic activities of hydroxychloroquine in rheumatic and related diseases. Current Medicinal Chemistry, 24 (20), 2241–2249.
   PubMed Web of Science ®Google Scholar
• Jorge, A., et al., 2018. Hydroxychloroquine retinopathy – implications of research advances for rheumatology care. Nature Reviews. Rheumatology, 14 (12), 693–703.
   PubMed Web of Science ®Google Scholar
• Lewis, K., et al., 2021. The efficacy and safety of hydroxychloroquine for COVID-19 prophylaxis: a systematic review and meta-analysis of randomized trials. PLoS One, 16 (1), e0244778.
   PubMed Web of Science ®Google Scholar
• Li, G., et al., 2021a. Safety and efficacy of artemisinin-piperaquine for treatment of COVID-19: an open-label, non-randomised and controlled trial. International Journal of Antimicrobial Agents, 57 (1), 106216.
   PubMed Web of Science ®Google Scholar
• Li, X., et al., 2021b. Pharmacokinetics and toxicokinetics of artemisinin-hydroxychloroquine sulfate tablets in rats and dogs. Evidence-Based Complementary and Alternative Medicine, 2021, 6830459.
   PubMedGoogle Scholar
• Li, Q., and Hickman, M., 2011. Toxicokinetic and toxicodynamic (TK/TD) evaluation to determine and predict the neurotoxicity of artemisinins. Toxicology, 279 (1–3), 1–9.
   PubMed Web of Science ®Google Scholar
• Li, X., et al., 2022. Acute and subacute oral toxicity of artemisinin-hydroxychloroquine sulfate tablets in rats. Regulatory Toxicology and Pharmacology, 129, 105114.
   PubMed Web of Science ®Google Scholar
• Li, X., et al., 2019. Sub-acute toxicological study of artemisinin-piperaquine tablets in rhesus monkeys. Regulatory Toxicology and Pharmacology, 109, 104486.
   PubMed Web of Science ®Google Scholar
• Liu, J., et al., 2020. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discovery, 6 (1), 16.
   PubMed Web of Science ®Google Scholar
• Marques, M.M., et al., 2014. Plasmodium vivax chloroquine resistance and anemia in the western Brazilian Amazon. Antimicrobial Agents and Chemotherapy, 58 (1), 342–347.
   PubMed Web of Science ®Google Scholar
• Medhi, B., et al., 2009. Pharmacokinetic and toxicological profile of artemisinin compounds: an update. Pharmacology, 84 (6), 323–332.
   PubMed Web of Science ®Google Scholar
• Menard, D., and Dondorp, A., 2017. Antimalarial drug resistance: a threat to Malaria elimination. Cold Spring Harbor Perspectives in Medicine, 7 (7), a025619.
   PubMed Web of Science ®Google Scholar
• Muller, O., Lu, G.Y., and von Seidlein, L., 2019. Geographic expansion of artemisinin resistance. Journal of Travel Medicine., 26 (4), taz030.
   PubMed Web of Science ®Google Scholar
• Nicol, M.R., et al., 2020. Pharmacokinetics and pharmacological properties of chloroquine and hydroxychloroquine in the context of COVID-19 infection. Clinical Pharmacology and Therapeutics, 108 (6), 1135–1149.
   PubMed Web of Science ®Google Scholar
• Oscanoa, T.J., et al., 2020. Frequency of long QT in patients with SARS-CoV-2 infection treated with hydroxychloroquine: a meta-analysis. International Journal of Antimicrobial Agents., 56 (6), 106212.
   PubMed Web of Science ®Google Scholar
• Pasupureddy, R., et al., 2019. Current scenario and future strategies to fight artemisinin resistance. Parasitology Research, 118 (1), 29–42.
   PubMed Web of Science ®Google Scholar
• Shibeshi, W., et al., 2021. Efficacy and safety of artemisinin-based combination therapies for the treatment of uncomplicated malaria in pediatrics: a systematic review and meta-analysis. BMC Infectious Diseases, 21 (1), 326.
   PubMed Web of Science ®Google Scholar
• Sperati, C.J., and Rosenberg, A.Z., 2018. Hydroxychloroquine-induced mimic of renal Fabry disease. Kidney International, 94 (3), 634.
   PubMed Web of Science ®Google Scholar
• The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). 2009. Guidance on nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals.
   Google Scholar
• United States Food and Drug Administration (FDA). 1996. Guidance for industry: single dose acute toxicity testing for pharmaceuticals.
   Google Scholar
• van der Pluijm, R.W., et al., 2019. Determinants of dihydroartemisinin-piperaquine treatment failure in Plasmodium falciparum malaria in Cambodia, Thailand, and Vietnam: a prospective clinical, pharmacological, and genetic study. Lancet Infectious Diseases., 19 (9), 952–961.
   PubMed Web of Science ®Google Scholar
• Wang, X., et al., 2020. Artemisinin inhibits the replication of flaviviruses by promoting the type I interferon production. Antiviral Research, 179, 104810.
   PubMed Web of Science ®Google Scholar
• Watson, J.A., et al., 2020. Concentration-dependent mortality of chloroquine in overdose. eLife, 9, e58631.
   PubMed Web of Science ®Google Scholar
• Whegang Youdom, S., Chiabi, A., and Basco, L.K., 2019. Monitoring the efficacy and safety of artemisinin-based combination therapies: a review and network meta-analysis of antimalarial therapeutic efficacy trials in cameroon. Drugs in R&D, 19 (1), 1–14.
   PubMed Web of Science ®Google Scholar
• World Health Organization. 2021. World malaria report 2021.
   Google Scholar
• Zhang, J., and Yan, C., 2005. Pharmacological and toxicological studies of artemisinins. Journal of Hebei North University, 22 (6), 75–77. In Chinese).
   Google Scholar